Company Encyclopedia
View More
name
Simplify Health Care ETF
PINK.US
News
View More

Berger Financial Group Inc Has $4.64 Million Holdings in AbbVie Inc. $ABBV

Berger Financial Group Inc increased its stake in AbbVie Inc by 41.2% during the third quarter, now holding 20,025 shares valued at $4.64 million. Other institutional investors also adjusted their positions in AbbVie. The company reported strong quarterly earnings, with a revenue increase of 9.1% year-over-year and a dividend increase to $1.73 per share. Analysts have given positive ratings, with some upgrading AbbVie's stock to a 'buy' or 'strong-buy.'

Market Beat·
US
ABBV
+0.48%
Market Beat·
US
ABBV
+0.48%

Bio-Techne Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Bio-Techne Corp.'s stock rose 1.18% to $58.96 on Monday, marking its third consecutive day of gains. Despite this, it underperformed compared to competitors like Amgen Inc. and Charles River Laboratories, which saw higher gains. Bio-Techne remains 25.63% below its 52-week high of $79.28. The S&P 500 and Dow Jones also saw gains on the same day.

Dow Jones·
US
CRL
+3.02%
US
AMGN
+1.22%
US
TECH
+1.18%
Dow Jones·
US
CRL
+3.02%
US
AMGN
+1.22%
US
TECH
+1.18%

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma | REGN Stock News

Regeneron Pharmaceuticals and Sanofi announced that Japan's Ministry of Health, Labour and Welfare approved Dupixent® (dupilumab) for children aged 6 to 11 with severe asthma. This approval is based on a Phase 3 trial showing significant reduction in exacerbations and improved lung function. Dupixent is the first biologic to show such benefits in this age group. It is already approved for various conditions in over 60 countries.

StockTitan·
US
SNYNF
+1.46%
US
REGN
+1.48%
StockTitan·
US
SNYNF
+1.46%
US
REGN
+1.48%

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Regeneron Pharmaceuticals Inc. (REGN) stock rose 1.48% to $779.36 on Monday, outperforming some competitors. The S&P 500 Index increased by 0.64% and the Dow Jones Industrial Average by 0.47%. This marks the stock's second consecutive day of gains, closing 1.47% below its 52-week high. Trading volume was below the 50-day average.

Dow Jones·
US
REGN
+1.48%
Dow Jones·
US
REGN
+1.48%

Gilead Sciences Executives to Present at J.P. Morgan Healthcare Conference

Gilead Sciences Inc. will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 11:15 a.m. PT. The live webcast will be available at investors.gilead.com, with a replay accessible for 30 days. Disclaimer: This AI-generated content is for informational purposes only and not financial, investment, or legal advice.

Reuters·
US
GILD
-0.10%
Reuters·
US
GILD
-0.10%
© 2025 Longbridge｜Disclaimer